PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while Biotechnology median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
100.00%
Gross profit growth of 100.00% while Biotechnology median is zero. Walter Schloss might see a slight advantage that could be built upon.
-2.59%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-2.59%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-10.34%
Negative net income growth while Biotechnology median is 1.61%. Seth Klarman would investigate factors dragging net income down.
-10.26%
Negative EPS growth while Biotechnology median is 6.25%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-10.26%
Negative diluted EPS growth while Biotechnology median is 6.25%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.08%
Share reduction exceeding 1.5x Biotechnology median of 0.39%. Joel Greenblatt would applaud significant buybacks if they are value-accretive.
0.08%
Diluted share reduction exceeding 1.5x Biotechnology median of 0.36%. Joel Greenblatt would see a meaningful advantage if shares are undervalued.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Negative OCF growth while Biotechnology median is -9.49%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-94.42%
Negative FCF growth while Biotechnology median is -6.26%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
OCF/share CAGR of 81.91% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
68.32%
OCF/share CAGR of 68.32% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
41.88%
3Y OCF/share growth of 41.88% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
55.55%
Net income/share CAGR of 55.55% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
79.95%
Net income/share CAGR of 79.95% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
56.07%
3Y net income/share CAGR of 56.07% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
188.20%
Equity/share CAGR of 188.20% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-69.82%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
327.49%
3Y equity/share CAGR of 327.49% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-14.02%
Negative BV/share change while Biotechnology median is -9.95%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-4.69%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
7.04%
We slightly increase R&D while Biotechnology is cutting. Peter Lynch sees a chance to grab market share with new offerings if ROI is managed well.
-5.63%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.